Manjool Shah, MD, clinical associate professor of ophthalmology and visual sciences for the Kellogg Eye Center, discussed how ...

Glaucoma diagnostics and imaging technology represent a rapidly evolving area at the intersection of clinical ophthalmology, biomedical engineering, and ...

Detailed price information for Sight Sciences Inc (SGHT-Q) from The Globe and Mail including charting and trades.

A new study warns that a widely used eye ointment can damage a popular glaucoma implant. Researchers found that oil-based ...

Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative ...

The 24-month study showed significant IOP and medication reductions with standalone OMNI use, with two-thirds of patients medication-free at 24 months. Retrospective analysis of African American eyes ...

MENLO PARK, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, ...

Sight Sciences (Nasdaq:SGHT) today announced new clinical data supporting its Omni minimally invasive glaucoma surgery (MIGS) device. Menlo Park, California–based Sight Sciences conducted a systematic ...

Sight Sciences Inc. (NASDAQ:SGHT) on Tuesday announced that UnitedHealthcare has updated its Glaucoma Surgical Treatments policy to cover goniotomy, trabeculotomy, canaloplasty (ab interno), and ...